Major Shareholder Converts Preferred Stock to 6.65% Common Stake Amidst Merger Activity

summarizeSummary

A major shareholder converted preferred stock into a 6.65% common equity stake, valued at over $1.1 million, and committed to supporting the company's pending merger with Obsidian Therapeutics.

check_boxKey Events

• Preferred Stock Conversion

  Parvinder Singh Hyare converted 13,521.292 shares of Series B Non-Voting Convertible Preferred Stock into 13,521,921 shares of common stock, effective May 15, 2026.

• Significant Common Stock Holding

  Following the mandatory conversion, Mr. Hyare beneficially owns 13,521,921 shares of common stock, representing approximately 6.65% of the outstanding shares.

• Support for Obsidian Merger

  Mr. Hyare is party to a Stockholder Support Agreement, committing to vote all eligible shares in favor of the definitive merger agreement with Obsidian Therapeutics.

• Context of Prior Mergers

  The Series B Preferred Stock originated from the Nova Pharmaceuticals merger in December 2024, and this conversion is a step in the company's ongoing capital structure adjustments amidst its pending merger with Obsidian Therapeutics.

auto_awesomeAnalysis

Parvinder Singh Hyare, a significant shareholder, converted 13,521.292 shares of Series B Preferred Stock into 13,521,921 shares of common stock, representing 6.65% of the company. This conversion, valued at over $1.1 million based on current prices, makes his substantial stake more liquid. The filing also confirms his support for the pending merger with Obsidian Therapeutics, which is a critical step for the company's future given its ongoing going concern warnings.